TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24452943
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment without dietary change (control group, 18 subjects)
Study: 24452943
Drug: Overall antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antihypertensive treatment
Study: 18681100
Drug: Twice-weekly strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly strength training over 2 years
Study: 8717556
Drug: 100mg aspirin
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin daily
Study: 24791969
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg/kg
Study: 24791969
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.15 ml/kg (Control Group C)
Study: 23261045
Drug: High-Dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose (HD) trivalent inactivated influenza vaccine (60μg of hemagglutinin per strain)
Study: 23261045
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) trivalent inactivated influenza vaccine (15μg of hemagglutinin per strain)
Study: 23261045
Drug: High-Dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose (HD) trivalent inactivated influenza vaccine
Study: 23261045
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) trivalent inactivated influenza vaccine
Study: 20880602
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid therapy (ALA)
Study: 15146341
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy in the early (prepsychotic) prodromal state
Study: 15146341
Drug: Amisulpride treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride treatment in the late prodromal (early psychotic) state
Study: 15146341
Drug: Normal clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal clinical treatment
Study: 2569848
Drug: Succinylcholine (Suc)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Suc) infusion
Study: 4817160
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (25 g) in the morning
Study: 4817160
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (25 g) in the afternoon
Study: 31634193
Drug: Recombinant gp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant gp120 protein vaccine (Vax004 clinical trial)
Study: 21527603
Drug: Cyclic parenteral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic parenteral nutrition (PN) with DEHP exposure
Study: 18772101
Drug: Prostaglandin analogues
Normalized name: Prostaglandin analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin analogues administered by non-invasive routes
Study: 8839903
Drug: CEF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (cyclophosphamide 600 mg/sqm i.v., epidoxorubicin 60 mg/sqm i.v. and fluorouracil 600 mg/sqm i.v.)
Study: 8839903
Drug: DES-CEF (diethylstilbestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-CEF (diethylstilbestrol 1 mg orally days 1-3, CEF on day 4)
Study: 1948120
Drug: Simultaneous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemotherapy with 25 mg/m2 of 4-epirubicin intravenously for 18 weeks after surgical castration.
Study: 1948120
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with surgical castration and long-term administration of flutamide without initial chemotherapy.
Study: 6842023
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) therapy
Study: 31960396
Drug: Aromatherapy (20-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (20-min inhalation of essential oil every night for 4 weeks)
Study: 31960396
Drug: Control (20-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20-min inhalation of sweet almond oil every night for 4 weeks)
Study: 22739394
Drug: Nevirapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (50 mg), Stavudine (6 mg), Lamivudine (30 mg) in fixed dose combination tablet (Triomune Baby)
Study: 14678081
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 (0, 25, 75, or 200 mg)
Study: 9675622
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg three times a day with 125 mg MK-0591 twice a day
Study: 9675622
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg three times a day with placebo for MK-0591
Study: 9675622
Drug: MK-0591 125
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 125 mg twice a day with placebo for ibuprofen
Study: 9675622
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Ibuprofen and MK-0591)
Study: 15642960
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with sulfadoxine-pyrimethamine plus artesunate
Study: 11320018
Drug: Initial medication
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medication (n = 307)
Study: 9263611
Drug: Ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (600 mg/day, T.D.D.) with 500 mg/day of calcium
Study: 7950502
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 500 mg/day of calcium
Study: 7659481
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (DTaP)
Study: 8426770
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis vaccine (DTwP)
Study: 3723990
Drug: Doxorubicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (15 mg/m2, 4 times per 48 h)
Study: 21077043
Drug: Continuous blood
Normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous blood purification (CBP) treatment (CVVH)
Study: 10048679
Drug: Azithromycin suspension
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin suspension for 5 days
Study: 10048679
Drug: Amoxicillin-clavulanate for
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate for 10 days (for those <5 years)
Study: 10048679
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate suspension (for those >=5 years)
Study: 10048679
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control children (no treatment)
Study: 2289214
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg twice a day for 21 days
Study: 27624622
Drug: Neladenoson bialanate
Normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neladenoson bialanate 30 mg single dose
Study: 27624622
Drug: Neladenoson bialanate
Normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neladenoson bialanate 10 mg for 7 days
Study: 27624622
Drug: Neladenoson bialanate
Normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neladenoson bialanate 20 mg for 7 days
Study: 20682612
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine (NAC) with intravenous hydration
Study: 20682612
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration only
Study: 19246588
Drug: Prandial strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial strategy (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l)
Study: 19246588
Drug: Basal strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal strategy (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l)
Study: 15146410
Drug: Full-dosage etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day)
Study: 15146410
Drug: Etanercept only
Normalized name: Etanercept only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept only (25 mg twice weekly)
Study: 15146410
Drug: Half-dosage etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day)
Study: 9408807
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once daily for 15 days) with terfenadine (60 mg twice daily for 8 days)
Study: 9408807
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg twice daily for 8 days) alone
Study: 7969324
Drug: Perioperative nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative nutritional support (intravenous solution enriched with 35% branched-chain amino acids, dextrose, and lipid emulsion for 14 days)
Study: 3297129
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid 20 mg/d if marrow blasts ≤ 5% or cytosine arabinoside 10 mg/d subcutaneously on 6 d/week if marrow blasts 6-30%, retinoic acid added after 12 weeks
Study: 3297129
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving conventional supportive therapy
Study: 30022571
Drug: isCGM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: isCGM group (26 participants, blinded for SMBG, insulin dosing based on isCGM)
Study: 30022571
Drug: SMBG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMBG group (20 participants, blinded for isCGM, insulin dosing based on SMBG)
Study: 27222271
Drug: CEP-26401 (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-26401 (0.02 to 5 mg single dose; 0.02 to 0.5 mg once daily multiple dosing)
Study: 20504165
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPnC) with 1 mg of CPG 7909 adjuvant
Study: 10648327
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion (Control)
Study: 6094448
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later (Group A)
Study: 6094448
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later, associated with ornidazole or metronidazole 0.5 g intravenous at the induction of anaesthesia and 0.5 g intravenous with the last injection of cefotaxime (Group B)
Study: 23475451
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (N=97) including education about blood‐borne diseases and referrals for testing and vaccinations
Study: 21176079
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks as induction therapy, followed by three once-weekly instillations at 3, 6, 12 and 18 months)
Study: 21176079
Drug: BCG non-maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG non-maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks)
Study: 21176079
Drug: Epirubicin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin therapy (40 mg, intravesically instilled nine times)
Study: 20205984
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isoflavones
Study: 17413839
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg isoflavones)
Study: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (Tio) plus transdermal tulobuterol (Tulo) 18 μg once daily plus 2 mg once daily for 4 weeks
Study: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (Tio) 18 μg once daily for 4 weeks
Study: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (Tio) plus transdermal tulobuterol (Tulo)
Study: 11467343
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) infusion of α-Lipoic acid (LA)
Study: 11467343
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of α-Lipoic acid (LA)
Study: 9663825
Drug: CDP571 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (5 mg/kg, single intravenous infusion)
Study: 8245892
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of acyclovir twice daily
Study: 8245892
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment (ES)
Study: 8245892
Drug: Open-label acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label acyclovir suppressive therapy
Study: 3516408
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray, dosage 1 mg
Study: 27898164
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg IV)
Study: 25842461
Drug: SRP combined
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel and doxycycline for 2 weeks
Study: 25842461
Drug: SRP combined
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel
Study: 20124186
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg/d (1,125 mg loading dose, day 1)
Study: 20124186
Drug: Lomustine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomustine (100 to 130 mg/m2, day 1)
Study: 10081852
Drug: BCG (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (120 mg, Danish strain 1331)
Study: 2194987
Drug: Phenylpropanolamine 25
Normalized name: phenylpropanolamine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine 25 mg
Study: 665568
Drug: 14.2 g
Normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.2 g of hemicellulose supplement per subject per day
Study: 665568
Drug: 14.2 g
Normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.2 g of cellulose supplement per subject per day
Study: 665568
Drug: 14.2 g
Normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.2 g of pectin supplement per subject per day
Study: 665568
Drug: 14.2 g
Normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.2 g of pectin plus 1.3 g of zinc
Study: 665568
Drug: 14.2 g
Normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.2 g of pectin plus 9.3 g of zinc
Study: 665568
Drug: 4.2 g
Normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 g of pectin plus 1.3 g of zinc
Study: 665568
Drug: 4.2 g
Normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 g of pectin plus 9.3 g of zinc
Study: 20878653
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (5 mL of liquid fibrin sealant sprayed before drains insertion)
Study: 19338151
Drug: Ginaton (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton (0.5 mg/kg)
Study: 10201475
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg/h continuous infusion after an initial 100-microg bolus)
Study: 7781346
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methylprednisolone
Study: 7781346
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg methylprednisolone
Study: 2150527
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg GBR 12909
Study: 2150527
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GBR 12909
Study: 2150527
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GBR 12909
Study: 2150527
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg GBR 12909
Study: 2150527
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg GBR 12909
Study: 2150527
Drug: GBR 12909
Normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBR 12909 (various doses)
Study: 376079
Drug: Brompton mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompton mixture (containing morphine, cocaine, ethyl alcohol, syrup BP, and chloroform water) administered orally
Study: 376079
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone in a flavoured aqueous solution administered orally
Study: 23812862
Drug: Intravenous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous interferon (IFN) administered during the anhepatic phase of liver transplantation, along with weight-based ribavirin and subcutaneous IFN at time of incision.
Study: 23812862
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous interferon).
Study: 20932360
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care cognitive behaviour therapy (CBT) - 10 sessions
Study: 20932360
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (second phase)
Study: 20932360
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (third phase)
Study: 20932360
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care cognitive behaviour therapy (CBT)
Study: 23423871
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene 0.1% cream
Study: 11251629
Drug: SR 48968C
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48968C (100 mg orally once daily for 9 days)
Study: 30777117
Drug: Xuebijing (XBJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing (XBJ) injection
Study: 30777117
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl injection (placebo control)
Study: 25607558
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine emulsion (CsAE)
Study: 16941406
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Aspirin (ASA) once daily
Study: 16941406
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Clopidogrel once daily
Study: 15385014
Drug: S(+)‐ketamine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1 mg x kg(‐1) (group K)
Study: 15385014
Drug: S(+)‐ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 0.5 mg x kg(‐1) plus clonidine 1 microg x kg(‐1) (group KC)
Study: 11222185
Drug: 1.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL/kg of low osmolality contrast medium
Study: 11222185
Drug: 150 mL
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL of low osmolality contrast medium
Study: 11222185
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of low osmolality contrast medium
Study: 9444494
Drug: Trimipramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine and adjunct bright-light therapy
Study: 7506176
Drug: nimesulide (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (50mg granules twice daily)
Study: 7506176
Drug: lysine-aspirin (360mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: lysine-aspirin (360mg granules twice daily)
Study: 29418016
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Study: 28678647
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5% gel